UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000016083
Receipt number R000018322
Scientific Title The preventive efficacy against a cold and influenza by continuous consumption of yogurt containing lactoferrin.
Date of disclosure of the study information 2014/12/29
Last modified on 2014/12/29 17:27:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The preventive efficacy against a cold and influenza by continuous consumption of yogurt containing lactoferrin.

Acronym

LF Yogurt in Fukushima

Scientific Title

The preventive efficacy against a cold and influenza by continuous consumption of yogurt containing lactoferrin.

Scientific Title:Acronym

LF Yogurt in Fukushima

Region

Japan


Condition

Condition

Nothing

Classification by specialty

Infectious disease Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy of yogurt including Lactoferrin for prevention infective diseases such as cold and influenza, and to contribute to the development of effective health activities for employees.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Affected with infective diseases or not

Key secondary outcomes

SF-36, STAI (State-Trait Anxiety Inventory), The sense effect


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

In LF yogurt group, participants eat 1 cup of yogurt once a day including 100mg Lactoferrin for 16 weeks.

Interventions/Control_2

In control group, participants don't receive LF yogurt, and live with their usual lifestyles for 16 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1)Employees of Fukushima prefecture companies.
(2)Those whose age at the time of informed consent is 20 and over.
(3)Those who can understand the purpose and the contents of this study, and can agree with participation by letter.

Key exclusion criteria

(1)The presence of allergic response to milk product.
(2)Those who have taken medical supplies or supplements which investigator judged that this trial would be affected.
(3)Those who are under treatment of severe disease such as cancer.
(4)Those who have excised the digestive organ.
(5)Pregnancy or beast-feeding.
(6)In addition, those who were judged inadequate by investigator.

Target sample size

400


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takeshi Tanigawa

Organization

Graduate School of Medicine, Ehime University

Division name

Department of Public Health

Zip code


Address

Shizukawa, Toon-city, Ehime

TEL

089-960-5283

Email

tt9178tt9178@gmail.com


Public contact

Name of contact person

1st name
Middle name
Last name Tetsu Kinoshita

Organization

Community Life Sciences Co., Ltd.

Division name

Social Epidemiology Institute

Zip code


Address

160-4 Kishimachi, Matsuyama-city, Ehime

TEL

089-904-7811

Homepage URL


Email

tetsu.prospective@gmail.com


Sponsor or person

Institute

Department of Public Health, Graduate School of Medicine, Ehime University

Institute

Department

Personal name



Funding Source

Organization

Morinaga Milk Industry Co.,Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 12 Month 29 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 09 Month 24 Day

Date of IRB


Anticipated trial start date

2012 Year 11 Month 15 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 12 Month 29 Day

Last modified on

2014 Year 12 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018322


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name